Texas High Court Sides With Big Pharma in Janssen Failure-to-Warn Case

, The Litigation Daily

   |1 Comments

The pharmaceutical industry scored a big win on Friday in the Supreme Court of Texas. Not only did the court knock out a $3.6 million verdict against a Johnson & Johnson subsidiary that makes the drug Remicade, but it set a new, tougher standard in the state for bringing cases alleging failure-to-warn and fraud.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

  • W Michael Shinkle

    Unless I am doing something wrong, when I click on the link to the plaintiffs' brief, I get the petitioner's brief. Clicking on the link to Centocor's appellate brief, produces the correct result; but you get the same brief when you click on the link to the plaintiffs' brief.

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202558984346

Thank you!

This article's comments will be reviewed.